Nobuko Maruyama

Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus

Hiroyuki Tanaka, Kazuhiko Takano, Hiroaki Iijima et al. · Advances in Therapy · 2016 · 141 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, 12‐week study

Nobuya Inagaki, Kazuoki Kondo, Toru Yoshinari et al. · Diabetes Obesity and Metabolism · 2013 · 137 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus

Nobuya Inagaki, Shin‐ichi Harashima, Nobuko Maruyama et al. · Cardiovascular Diabetology · 2016 · 71 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus

Hiroaki Iijima, Takayuki Kifuji, Nobuko Maruyama et al. · Advances in Therapy · 2015 · 69 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin

David Polidori, Hiroaki Iijima, Maki Goda et al. · Diabetes Obesity and Metabolism · 2018 · 64 citations · Full text

Medicine, Endocrinology, Pharmacology +14